Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 9/20 | 0.35 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | TYK2 | P29597 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17697521 | 0.82 | NPSR1 (0.31) | NPSR1 | |
| SCHEMBL16006449 | 0.75 | JAK2 (0.30) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL17761565 | 0.74 | — | — | |
| SCHEMBL16154694 | 0.72 | — | — | |
| SCHEMBL31648311 | 0.69 | ALDH1A1 (0.44) | ALDH1A1GAAEPHX2LMNANPSR1 | |
| SCHEMBL31648531 | 0.68 | ALDH1A1 (0.46) | ALDH1A1GAAEPHX2LMNAPTGDR2 | |
| SCHEMBL31648570 | 0.67 | EPHX2 (0.44) | ALDH1A1GAAEPHX2LMNASLC22A12 | |
| SCHEMBL23793284 | 0.66 | EPHX2 (0.40) | ALDH1A1GAAEPHX2LMNASLC22A12 | |
| SCHEMBL19007302 | 0.65 | ALDH1A1 (0.65) | ALDH1A1GAALMNAPTGDR2P2RX7 | |
| SCHEMBL15724345 | 0.65 | ALDH1A1 (0.46) | ALDH1A1GAAEPHX2LMNAPTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3954679-A2 | AMIDE COMPOUNDS FOR THE TREATMENT OF HIV INFECTIONS | Gilead Sciences, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3409667-B1 | AMIDE COMPOUNDS FOR THE TREATMENT OF HIV INFECTIONS | GILEAD SCIENCES INC (US) | 2021-07-21 | — | — | EP | disclosed |
| US-20210009555-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2021-01-14 | — | — | US | disclosed |
| EP-3409667-A1 | AMIDE COMPOUNDS FOR THE TREATMENT OF HIV INFECTIONS | Gilead Sciences, Inc. (US) | 2018-12-05 | — | — | EP | disclosed |
| US-20180273508-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2018-09-27 | — | — | US | disclosed |
| EP-2961742-B1 | AMIDE COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES INC (US) | 2018-08-01 | — | — | EP | disclosed |
| US-9951043-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20160108030-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-04-21 | — | — | US | disclosed |
| EP-2961742-A2 | AMIDE COMPOUNDS FOR THE TREATMENT OF HIV | Gilead Sciences, Inc. (US) | 2016-01-06 | — | — | EP | disclosed |
| US-20140303164-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2014-10-09 | — | — | US | disclosed |
| WO-2014134566-A2 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-09-04 | — | — | WO | disclosed |
| WO-2013006792-A1 | ANTIVIRAL COMPOUNDS | PHARMARESOURCES (SHANGHAI) CO., LTD. (CN) | 2013-01-10 | — | — | WO | disclosed |
| WO-2013006792-A1 | ANTIVIRAL COMPOUNDS | PHARMARESOURCES (SHANGHAI) CO., LTD. (CN) | 2013-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180273508-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, RPL35 | ALDH1A1 351/4885GAA 17/4885EPHX2 2991/4885 |
| US-20210009555-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, RPL35 | ALDH1A1 351/4885GAA 17/4885EPHX2 2991/4885 |
| US-20160108030-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, RPL35 | ALDH1A1 351/4885GAA 17/4885EPHX2 2991/4885 |
| US-20140303164-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, G6PD | ALDH1A1 372/4885GAA 18/4885EPHX2 3048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.